TaiMed is exploring how TMB-365 can serve not only as a therapeutic antibody, but also as a targeting vehicle for antibody-drug conjugates (ADCs). The goal is to use CD4-directed delivery to concentrate selected therapeutic payloads in relevant CD4+ cells while limiting unnecessary systemic exposure.
The challenge: the latent HIV reservoir
Effective antiretroviral therapy can suppress HIV to undetectable levels, but it does not eliminate the latent viral reservoir - long-lived CD4+ T cells that harbor dormant HIV. This reservoir is a central barrier to achieving durable HIV control without ongoing antiretroviral therapy.
A CD4-targeted delivery concept
TaiMed's preclinical HIV ADC strategy uses TMB-365 as the targeting component. By directing a therapeutic payload to CD4+ cells, the platform is being studied as a potential way to act more selectively at cells associated with the viral reservoir.
Target specificity | TMB-365-based constructs demonstrated binding to CD4+ target cells in preclinical studies.
Internalization | Preclinical work demonstrated uptake of the antibody-drug construct into target cells.
Payload release | Studies demonstrated intracellular release of the attached payload.
In vitro activity | Preclinical experiments demonstrated antiviral activity in vitro.
The long-term objective of TaiMed's HIV ADC research is to contribute to strategies aimed at durable viral control without continuous antiretroviral therapy. This remains an early research goal and will require substantial additional preclinical and clinical validation.
TaiMed is also exploring whether the same CD4-targeting concept could support precision delivery in autoimmune and other immune-mediated diseases in which dysregulated CD4+ T-cell activity contributes to pathology. These programs remain discovery-stage or preclinical.
Preclinical research only. Safety and efficacy have not been established in humans, and no CD4-ADC product has been approved for HIV cure or autoimmune disease.
Contact CDMO Service